Skip to Main Content

Paper Details

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Nat Commun
38
2020
AZD2014, FKBP, FKBP prolyl isomerase 9, FKBP9, GBM, GBM proteomic cluster 1 (GPC1) tumors, GPC1, GPC2, GPC2 tumors, IDH, IDH mutant, IDH wild-type GBMs, PDCs, PHGDH, glioblastoma, isocitrate, isocitrate dehydrogenase, isocitrate dehydrogenase 1/2, low, low-grade glioma, mTORC1/2, neural, patient, patient-derived cells, phosphoglycerate, phosphoglycerate dehydrogenase, tumors
Author NameAffiliation
Hee Jin ChoInstitute for Refractory Cancer Research, Samsung Medical Center
Hee Jin ChoPrecision Medicine Research Institute, Samsung Medical Center
Jason K SaKorea University College of Medicine
Jayeon KimInstitute for Refractory Cancer Research, Samsung Medical Center
Jayeon KimPrecision Medicine Research Institute, Samsung Medical Center
Do-Hyun NamInstitute for Refractory Cancer Research, Samsung Medical Center
Do-Hyun NamSungkyunkwan University
Do-Hyun NamSamsung Medical Center, Sungkyunkwan University School of Medicine
Do-Hyun NamInstitute for Refractory Cancer Research, Samsung Medical Center
Do-Hyun NamSamsung Medical Center, Sungkyunkwan University School of Medicine
Do-Hyun NamSungkyunkwan University
Hyun Seok KimSeverance Biomedical Science Institute, Yonsei University College of Medicine
Hyun Seok KimYonsei University College of Medicine
  • 1 - 13

Datasets

Release 1.2